Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?

  • 0University of Michigan, Department of Medicine, Division of Medical Oncology, Ann Arbor, MI, USA.

|

|

Summary

No abstract available on PubMed